BMS bet looking good as Augtyro approved in ROS1-positive NSCLC

16 November 2023
bristol_myers_squibb_shutterstock_large

Bristol Myers Squibb (NYSE: BMY) has announced that the US Food and Drug Administration (FDA) has approved Augtyro (repotrectinib) to treat locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).

The US pharma major acquired the oral therapy - a tyrosine kinase inhibitor (TKI) targeting ROS1 oncogenic fusions - from Turning Point Therapeutics (Nasdaq: TPTX) for $4.1 billion last year.

This approval is based on the pivotal TRIDENT-1 trial, in which Augtyro successfully achieved a high objective response rate and durable response.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology